Xilis Inc.
- UEI
- HUBZGFA8NE97
- CAGE
- 8G7U3
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- xilis.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| An integrated microfluidic device for patient-derived micro-organospheres - project summary/abstract functional… | National Cancer Institute | $5,675,220 | |
| Micro-organospheres drug screen to lead care (model): a precision oncology platform to guide breast cancer therapy -… | National Cancer Institute | $1,795,478 | |
| Tissue-derived droplet micro-organospheres as models for high-throughput testing of pathogens | Defense Advanced Research Projects Agency | $224,658 |
About Xilis Inc.
Xilis Inc. is a for-profit manufacturing company that is revolutionizing precision oncology and drug development. The company has developed the MicroOrganoSphereTM (MOS) technology and Precision Oncology Platform, which are transforming treatment choices in the clinic and bringing novel therapies to patients.
Xilis Inc. has received a Small Business Innovation Research (SBIR) Phase I contract from the Defense Advanced Research Projects Agency (DARPA) for the development of tissue-derived droplet micro-organospheres as models for high-throughput testing of pathogens. The firm fixed-price contract, valued at $224,658.00, was set aside for small businesses. Xilis Inc. has also been awarded a Project Grant from the National Cancer Institute to develop an automated, end-to-end microfluidic instrument called the "MOSGEN" that can rapidly generate patient-derived micro-organospheres (MOS). The $1,199,214 award supports the development of a penultimate prototype in Phase I and the build-out of a commercial-grade MOSGEN instrument in Phase II, enabling robust functional precision medicine capabilities and validating the instrument's operations through clinical trial collaborations with MD Anderson Cancer Center and Mayo Clinic.
Additionally, Xilis Inc. has received two other Project Grants from the National Cancer Institute. One grant, worth $1,795,478.00, aims to develop and validate the company's Micro-Organosphere Drug Screen to Lead Care (MODEL) platform, a precision oncology platform to guide breast cancer therapy. The other grant supports the development of a novel microfluidics technology that generates patient-derived micro-organospheres (PDMO) from clinical samples and performs drug screening within 10 days to guide therapy. Both grants involve collaborations with various partners, including MD Anderson Cancer Center, Mayo Clinic, and Duke University, among others.
Quick answers
What is Xilis Inc.'s UEI?
Xilis Inc.'s Unique Entity ID (UEI) in SAM.gov is HUBZGFA8NE97.
What is Xilis Inc.'s CAGE code?
Xilis Inc.'s CAGE code is 8G7U3.
What is Xilis Inc.'s primary NAICS code?
Xilis Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Xilis Inc. registered in SAM.gov?
Xilis Inc.'s SAM.gov registration expired on September 5, 2026.
What is Xilis Inc.'s most recent federal award?
Xilis Inc.'s most recent federal grant award is An integrated microfluidic device for patient-derived micro-organospheres - project summary/abstract functional… (R44CA287952), from National Cancer Institute, on September 20, 2023.
On GovTribe
See Xilis Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors